PKC Activator Induces IgA Class Switching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases primarily focus on symptomatic relief and do not address the underlying immune response, with a lack of effective therapies to prevent or treat allergic reactions caused by excessive IgE production.
Innovation Solution
A pharmaceutical composition containing a PKC activator that induces selective class switching in B cells from IgE to IgA production, suppressing IgE production and enhancing IgA production, thereby treating or preventing allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic treatment drugs (antihistamine, steroid) are administered, then allergic symptoms are temporarily relieved, but the underlying immune response causing IgE production is not addressed and treatment effectiveness is insufficient
Solution Approach 1:
The invention extracts and targets the specific molecular mechanism (PKC activation) that controls class switching in B cells. By isolating and modulating this specific pathway with PKC activators, the treatment addresses the root cause of IgE production rather than merely suppressing symptoms, thereby extracting the essential therapeutic target from the complex immune system.
Solution Approach 2:
The invention changes the immunological parameter of class switching preference from IgE toward IgA by modulating PKC activity. This parameter change in B cell differentiation direction fundamentally alters the immune response profile, transforming the therapeutic approach from symptom management to immune response redirection.
2Object-affected harmful factors
If class switching to IgA is induced in B cells, then IgE production is suppressed and allergic response is reduced, but selective induction without IgG or IgE induction must be achieved
Solution Approach 1:
The invention uses PKC activators as intermediary substances that mediate the class switching process in B cells. These intermediaries specifically target the molecular machinery controlling class switching, enabling selective induction of IgA while preventing IgE and IgG production through precise molecular interaction with the class switching pathway.
Solution Approach 2:
The invention applies local quality by inducing different antibody class outcomes in different contexts or dosage conditions. The PKC activator creates a localized effect on specific B cell populations or differentiation pathways, enabling selective IgA class switching while maintaining suppression of other classes through spatial or functional differentiation in the immune response.
3Object-generated harmful factors
If current immune suppression therapies are used, then immune reaction is suppressed at each stage, but they are not sufficient as therapeutic drugs and do not provide fundamental treatment
Solution Approach 1:
Instead of suppressing the immune response as current therapies do, the invention inverts the approach by actively inducing a protective immune response (IgA class switching) that naturally suppresses the harmful IgE response. This inversion transforms immune suppression therapy into immune redirection therapy, providing fundamental treatment by altering the direction rather than merely dampening the immune response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces IgE production and increases IgA production, providing a potential cure for allergic diseases by altering the immune response at the cellular level, offering a prophylactic and therapeutic solution for conditions like atopic dermatitis and asthma.
Implementation Method 1
induces selective class switching in B cells from IgE to IgA production
Implementation Method 2
pharmaceutical composition containing a PKC activator
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.